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Background: Deviations in composition and diversity of intestinal microbiota in infancy have been associated with
both the development and recurrence of atopic eczema. Thus, we decided to use a deep and global
microarray-based method to characterize the diversity and temporal changes of the intestinal microbiota in infancy
and to define specific bacterial signatures associated with eczema. Faecal microbiota at 6 and 18 months of age
were analysed from 34 infants (15 with eczema and 19 healthy controls) selected from a prospective follow-up
study based on the availability of faecal samples. The infants were originally randomized to receive either
Lactobacillus rhamnosus GG or placebo.
Results: Children with eczema harboured a more diverse total microbiota than control subjects as assessed by the
Simpson’s reciprocal diversity index of the microarray profiles. Composition of the microbiota did not differ
between study groups at age of 6 months, but was significantly different at age of 18 months as assessed by MCPP
(p=0.01). At this age healthy children harboured 3 -fold greater amount of members of the Bacteroidetes (p=0.01).
Microbiota of children suffering from eczema had increased abundance of the Clostridium clusters IV and XIVa,
which are typically abundant in adults. Probiotic Lactobacillus rhamnosus GG supplementation in early infancy was
observed to have minor long-term effects on the microbiota composition.
Conclusion: A diverse and adult-type microbiota in early childhood is associated with eczema and it may
contribute to the perpetuation of eczema.
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Major microbial colonization of the gastrointestinal tract
starts at delivery when an infant comes into contact with
the environment. The composition of developing micro-
biota is affected by factors such as mode of delivery
[1-3], dietary pattern [4,5] and administration of probio-
tics or antibiotics [6,7]. The early colonization events
and the commensal intestinal microbiota shape the* Correspondence: lotta.nylund@utu.fi
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reproduction in any medium, provided the orimmune system and potentially affect the development
of variety of diseases [8].
Previous studies have shown associations between the
composition of intestinal microbiota and atopic diseases.
Most of these have addressed the microbiota compos-
ition preceding the development of atopic disease, while
microbiota aberrancies in infants already suffering from
eczema have obtained less attention. Reduced diversity
at early life (i.e. at 1 week, 1 month or 4 months of age)
has been associated with an increased risk of developing
atopic disease [9-12]. The results on specific bacterial
species or groups that would either increase or decrease
the risk of developing allergy are still conflicting [13-15].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lergic children (i.e. after the onset of allergy) with also
conflicting results [16-19]. For example, faecal bifidobac-
terial counts have been reported to be both decreased
[17,18] or similar [16] as compared to healthy children.
Similarly, microbiota diversity in allergic children was
found to be decreased in one study [19] but not in an-
other [16]. Notably, the studies were conducted by using
traditional cultivation-based techniques or molecular
techniques that target a sub-set of the intestinal micro-
biota. Finally, the administration of specific probiotic
bacteria during pregnancy and/or during the first
months of life has been shown to reduce the risk of
atopy, especially atopic eczema [20-23]. However, some
studies have failed to find any connection between the
microbiota composition and development of atopic ec-
zema [24] or to confirm the role of probiotics in preven-
tion of atopic diseases [25,26].
A variety of high-throughput methods based on 16S
ribosomal RNA (rRNA) gene sequence analysis have
been established to analyse the intestinal microbiota in a
culture-independent way, including next -generation se-
quencing analysis and phylogenetic microarrays [27].
The high-density phylogenetic microarray HITChip con-
sists of 3699 unique 16S rRNA gene targeting oligo-
nucleotide probes that selectively recognise microbes at
different taxonomic levels [28]. This and other microar-
rays have shown to be instrumental for the comprehen-
sive and high-resolution analysis of the microbiota
composition from microbial species (or phylotypes) to
phylum-like level [28-30].
The objective of this study was to characterize the di-
versity and temporal changes of intestinal microbiota in
early childhood and to identify specific bacterial groups
associated with eczema. By using the HITChip micro-
array and strategic qPCR analysis of early life fecal sam-
ples, we detected specific differences in microbiota
composition between healthy children and those with
eczema.
Methods
Study design, subjects and faecal samples
Subjects of this study represent a sub-population from a
prospective follow-up trial at Turku University Central
Hospital, Finland, which has been described in detail
previously [20]. Briefly, the inclusion criterion for the
children was that they had a high risk of atopic diseases,
i.e. they had at least one close relative (mother, father
and/or sibling) with atopic eczema, allergic rhinitis or
asthma. Further inclusion criteria for present study were
vaginal delivery after full-term pregnancy (≥ 37 weeks),
normal birth weight (≥ 2500 g) and the availability of
faecal samples taken at the ages of 6 and/or 18 months.
Finally, all infants were exclusively or partially breast-fedfor at least four months. Based on these criteria, 34 chil-
dren from the original study population (n= 132) [20]
were included in this study. The basic characteristics of
the study subjects are shown in Additional file 1.
Mothers were randomized to receive capsules contain-
ing either placebo or 1 × 1010 colony-forming units of
Lactobacillus rhamnosus GG (ATCC 53103) daily for 2–
4 weeks before expected delivery. The intervention con-
tinued 6 months postnatally. The capsule contents were
consumed by mothers during the exclusive breastfeed-
ing, otherwise infants received the agents. The occur-
rence of eczema was diagnosed by the age of 2 years by
typical skin lesions found in children and chronic relaps-
ing course. This last criterion was fulfilled if the child
had had eczema for 1 month or longer at the 24-month
study visit and on at least one previous visit (at ages 3, 6,
12, 18 months). Eczema was considered atopic if it was
associated with positive skin prick test(s) at 6 and/or 24
-month study visit. None of the study subjects included
in present study suffered from asthma or allergic rhinitis.
Also, all the infants were normal weight at the age of 6
and 18 months of age.
The study protocol was approved by the Ethics Com-
mittee of the Hospital District of Southwest Finland and
subjects were enrolled in the study after written
informed consent was obtained.
Faecal samples and DNA extraction
The faecal samples were taken from children at age of 6
and 18 months. The samples were aliquoted and frozen
immediately after collection, and stored in −80°C. DNA
was extracted from faecal samples using the repeated
bead-beating method as described previously [31,32].
16S rRNA gene microarray analysis
The composition of total microbiota was assessed by
using the phylogenetic Human Intestinal Tract chip
(HITChip) as described previously [28,33], except for the
amplification step, where 25 cycles of end-point PCR
were used. Microarray analysis of all samples were per-
formed in at least two independent hybridizations until
satisfactory reproducibility was achieved (>96%). This
study reports results of more than 150 independent
microarray hybridizations.
The HITChip is a custom-made Agilent microarray
(Agilent Technologies, Palo Alto, CA, USA) designed to
comprehensively cover the diversity of the human intes-
tinal microbiota. The array contains 3699 unique oligo-
nucleotide probes targeting the V1 and V6 hypervariable
regions of the 16S rRNA gene and covering over 1100
intestinal bacterial phylotypes. The HITChip allows the
analysis at three phylogenetic levels: phylum-like level
(level 1), genus-like level (level 2) and phylotype level
(species-like, level 3). The details of the HITChip have
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Figure 1 Relative contribution of phylum-like bacterial groups
to the total HITChip signals of infants at 6 and 18 months of
age. Groups contributing for at least 1% (a) and at least 5% (b) to
the profiles are presented in the legend. The box extends from 25th
percentile to 75th percentile, with a line at the median; the whiskers
extent to the highest and lowest values. * Statistically significant
change (p < 0.05).
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phylogenetic fingerprinting and quantification [28].
Microarray data extraction and microbiota diversity
assessment
Data were extracted from microarray images using the
Agilent Feature Extraction software, version 9.5.1 (www.
agilent.com). Normalization of microarray data was per-
formed as described earlier [28,34]. Further data proces-
sing was performed by using a custom designed
relational database running under the MySQL database
management system (www.mysql.com) using R-based
scripts [28].
Quantitative PCR
Quantitative PCR (qPCR) analysis of Bifidobacterium
genus and species was carried out in an Applied Biosys-
tems 7300 Fast Real-Time PCR System in a 96-well for-
mat and by using SYBR Green chemistry (SYBR Green
PCR Master Mix, Applied Biosystems, USA). The pri-
mers and their specificities are presented in Additional
file 2. The PCR reactions and thermocycling conditions
were as reported earlier [35,36]. Standards for qPCR
were prepared as described in Nermes et al. [37]. Sam-
ples were analysed in duplicate in at least two independ-
ent runs.
Statistical and data analyses
Statistical analysis of both qPCR and HITChip data was
carried out with log-transformed data. In qPCR data,
non-detected values were imputed with the half of the
theoretical detection limit. For HITChip data, linear
models with factors for treatment, health status, time
point and breast-feeding with subsequent ANOVA and
contrast tests were used to determine the statistical dif-
ferences between groups. In microarray data, cut-off
values for positive responding probes were calculated as
described before [28]. In HITChip data the analysed
values were summary values on phylum-like and genus-
like level, obtained by summing the intensities from all
the probes assigned to the respective phylum-like or
genus-like phylogetic groups. Totally 19 phylum-like and
78 genus-like level groups reached the detection thresh-
old and were thus used in statistical analysis. The data is
presented as mean with standard deviation values. Re-
dundancy analysis (RDA) was performed by using the
multivariate statistical analysis package Canoco [38].
RDA plot shows bacterial groups principally contribut-
ing to the difference between the groups of subjects. The
significance of separation in RDA was assessed by Monte
Carlo Permutation Procedure (MCPP [39]).
The diversity of the microbial community assessed by
HITChip was expressed as Simpson’s reciprocal index of
diversity (1/D) as described before [28,40].Results
Temporal development of microbiota
The faecal microbiota of 34 children at age of 6 and 18
months was analysed using the HITChip phylogenetic
microarray. The diversity of total microbiota increased
significantly with age, as the Simpson’s the reciprocal di-
versity index has changed from 78 ± 24 to 111 ± 27 at
age of 6 and 18 months, respectively (p < .001). At the
phylum-like level, significant changes in the relative
abundances of major bacterial groups were detected
(Figure 1). The most prominent decline in abundance
was observed for Actinobacteria that contributed 24.2%
and 14.1% to the total signal at 6 and 18 months of age,
respectively (p= 0.01). Signal intensities for Actinobac-
teria were almost entirely obtained from bifidobacteria
(22.9% of the total microbiota at 6 months and 12.6%
at 18 months, p= 0.01). This finding was consistent
Figure 2 Simpson’s reciprocal index of diversity in healthy
children and children with eczema. The box extends from 25th
percentile to 75th percentile, with a line at the median; the whiskers
extent to the highest and lowest values. * Statistically significant
difference, p=0.03.
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ria counts decreased significantly with age (p= 0.03,
Additional file 3). At the species level, the amounts of B.
longum/infantis group, B. breve, B. bifidum, B. catenula-
tum group and B. adolescentis decreased over time as
assessed by qPCR. In addition to Actinobacteria, the
relative abundance of Bacilli decreased with age (from
11.8% to 7.1%, p= 0.03). All genus-like groups belonging
to Bacilli decreased, most of which not significantly as
individual groups, but the sum effect at the phylum-like
level was significant (Figure 1). An opposite trend was
observed for the bacterial groups belonging to the major
Clostridium clusters, especially members of the Clostrid-
ium cluster XIVa which relative abundance increased
with age from 42.0% to 55.6% (p= 0.02).Similar was
observed for Ruminococcus bromii et rel. group from
Clostridium cluster IV that increased from 0.13% to
0.34% (p=0.01). In total, 21 genus-like phylogenetic
groups changed significantly with age, (Table 1), which
further highlights the extensive compositional changes
that the microbiota is undergoing during this period
of life.
Analysis of the intestinal microbiota composition in
relation to the health status
When comparing the microbiota of the two groups of
children at the age of 18 months, pronounced differ-
ences were observed both in the microbial composition
and the diversity. Infants with eczema had a significantly
more diverse total microbiota (p=0.03, Figure 2). Ana-
lysis at the species-like level showed that a large number
of bacterial species have different abundance between
healthy and eczematous infants, although the individual
p-values are not particularly small (Additional file 4).
The numerous, but mostly not significant, differences atTable 1 Genus-like phylogenetic groups changing statistically
HITChip analysis
Phylum/order Genus-like phylogenetic group
Actinobacteria Bifidobacterium
Bacilli Lactobacillus plantarum et rel.
Clostridium cluster IV Ruminococcus bromii et rel.
Clostridium cluster IX Phascolarctobacterium faecium et rel.
Clostridium cluster XIVa Butyrivibrio crossotus et rel.
Clostridium symbiosum et rel.
Lachnobacillus bovis et rel.
Clostridium cluster XVIII Coprobacillus catenaformis et rel.
Fusobacteria Fusobacteria
Proteobacteria Proteus et rel.
Sutterella wadsworthia et rel.
Uncultured Mollicutes Uncultured Mollicutes
Genus-like groups with a p-value less than 0.01 are presented in the table.the species-like level prompted us to look at the trends
in microbiota differences at higher levels i.e. at the
phylum-like and genus-like levels. Analysis at the
phylum-like level showed that the most remarkable dif-
ference between the groups was observed in the Bacter-
oidetes, which were 3-fold more abundant in healthy
children at the age of 18 months (p= 0.01, Table 2). The
effect of Bacteroidetes is also clearly shown in the RDA
plot (Figure 3), which reveals the bacterial groups princi-
pally contributing to the difference among the groups of
subjects. The microbiota differences between the healthsignificantly from 6 to 18 months of age as assessed by
Mean relative abundances (SD)
6 months 18 months p-value
22.86 (15.92) 12.61 (9.51) 0.01
3.64 (5.41) 0.32 (0.49) 0.006
0.13 (0.25) 0.35 (0.37) 0.01
0.06 (0.01) 0.07 (0.01) 0.001
0.65 (0.43) 1.03 (0.63) 0.01
3.45 (2.17) 4.87 (1.97) 0.018
0.27 (0.21) 0.62 (0.60) 0.004
0.06 (0.01) 0.11 (0.07) 0.0002
0.07 (0.02) 0.09 (0.01) 0.001
0.07 (0.02) 0.09 (0.02) 0.002
0.08 (0.02) 0.10 (0.01) 0.003
0.12 (0.03) 0.14 (0.02) 0.002
Table 2 Statistically significant differences in microbiota of healthy and eczematous children
Phylum-like level Genus-like phylogenetic
group
Mean relative abundance* (SD)
18 months p-value
Healthy Eczema
Bacteroidetes 4.20 (4.21) 1.61 (0.36) 0.01
B. fragilis et rel. 0.49 (0.74) 0.13 (0.03) 0.01
B. ovatus et rel. 0.20 (0.23) 0.09 (0.02) 0.03
B. plebeius et rel. 0.08 (0.03) 0.06 (0.01) 0.02
B. stercoris et rel. 0.08 (0.03) 0.06 (0.01) 0.02
B. uniformis et rel. 0.12 (0.21) ND < .001
B. vulgatus et rel. 1.08 (1.80) 0.23 (0.15) 0.045
P. tannerae et rel. 0.06 (0.04) ND 0.03
Clostridium cluster IV C. leptum et rel. 0.97 (1.36) 1.78 (1.19) 0.03
R. bromii et rel. 0.25 (0.44) 0.44 (0.28) 0.03
C. cellulosi et rel. 0.81 (0.78) 1.27 (0.65) 0.03
Clostridium cluster XIVa R. lactaris et rel. 0.12 (0.16) 1.87 (2.83) 0.04
C. nexile et rel. 1.65 (0.80) 2.05 (0.85) 0.02
* % of total HITChip signal
ND, below the detection level.
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by MCPP (p= 0.01) and a total of 9.1% of the variation
within the dataset could be related to the health status
of the infants. In contrast to the Bacteroidetes, spe-
cific bacterial groups from the most abundant groups
of the Firmicutes phylum - Clostridium clusters IV and
XIVa - were significantly more abundant in children with
eczema (Table 2, Figure 4). In summary, the multiple dif-
ferences in specific bacterial groups result in microbiota
profiles that are significantly distinct between healthyFigure 3 RDA plot of the microbiota composition of healthy and ecze
that contributed more than 35% of the variability of the samples are indica
Procedure was 0.01. Abbreviations: B., Bacteroides, C., Clostridium, L., Lactoba
Ruminococcus.and eczematous infants as assessed by MCPP (p=0.01,
Figure 3).
Similar microbiota changes were observed between
children with eczema and healthy children when only
subjects in the placebo group were analysed, although
the differences between the groups did not reach statis-
tical difference due to the small number of subjects
(Additional file 5). No significant differences were
observed for the bifidobacterial sub-community between
the two groups of children using both HITChip andmatous children at 18 months of age. Responding bacterial groups
ted by blue arrows. P-value obtained by Monte Carlo Permutation
cillus, E., Eggerthella, Eub., Eubacterium, P., Papillibacter, R.,
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Figure 4 Relative contribution of phylum-like bacterial groups to the total HITChip signals of healthy and eczematous infants at 6 and
18 months of age. Groups contributing for at least 1% to the profiles are presented in the legend. * Statistically significant difference between
healthy children and children with eczema at 18 months (p= 0.01).
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list of phylum-like and genus-like level data and p-values
obtained by statistical analyses are presented in Additional
file 7 and Additional file 8, respectively.
Notably, an indication towards altered microbiota
composition in children with eczema was already identi-
fied at 6 months, although the difference did not reach
the level of statistical significance (MCPP, p=0.35). A
higher abundance of the Clostridium cluster XIVa bac-
teria was observed in infants with eczema than healthy
controls (mean relative abundances 45.1% and 39.1%,
respectively, p= 0.50).
L. rhamnosus GG supplementation in early infancy has
minor long-term effects on the microbiota composition
When comparing the levels of HITChip signals between
children from the placebo group and those who had
received L. rhamnosus GG for their first 6 months of life,
no statistically significant differences were observed at
the age of 6 months. However, the supplementation with
L. rhamnosus GG showed effects on three genus-like
bacterial groups at the age of 18 months i.e. a year after
the cessation of the probiotic supplementation. The chil-
dren that had received L. rhamnosus GG had higher
levels of the butyrate-producing groups Anaerostipes
caccae et rel (LGG 2.89 ± 2.13% and placebo 1.18 ±
0.91% of the total microbiota, p=0.03) and Eubacterium
ventriosum et rel (LGG 0.17 ± 0.11% and placebo 0.11 ±
0.07 of the total microbiota, p=0.04) than those ofplacebo group (Additional file 9). Moreover, the placebo
group children had higher levels of Clostridium difficile
et rel at 18 months of age as compared to the LGG
group children (1.19 ± 0.85% and 0.78 ± 0.60%, respect-
ively, p=0.047). The comprehensive list of phylum-like
and genus-like level data and p-values obtained by statis-
tical analyses are presented in Additional file 7 and
Additional file 8, respectively.
The effect of the probiotic supplementation on the
microbiota composition within the group of healthy chil-
dren or the group of children with eczema was not
addressed due to the small number of subjects.
Discussion
We used a high-throughput phylogenetic microarray to
reveal alterations in the gut microbiota composition
throughout early childhood. The used microarray has
been developed and validated for determining the micro-
biota diversity and evaluating the relative proportions of
genus-like or higher (phylum-like) phylogenetic groups
[28]. Moreover, it has been demonstrated that this
microarray has a power equal to or higher than deep
new generation sequencing [41] and it has previously
been used to compare the microbiota diversity and com-
position in a variety of studies [33,42].
Despite the highly significant increase of microbiota
diversity with age, the diversity indeces at 18 months of
age are still relatively low (~110) when compared to the
approximately two-fold higher indexes (150–200)
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suggested that by the age of 1 to 2 years the microbiota
resembles that of an adult [29,43]. Our results show that
microbiota succession continues at least until the age of
18 months and most likely even further, because the
bacterial diversity has still not reached the diversity of
an adult person. Thus, significant changes can be
expected to occur in even after 18 months of age.
Concerning the microbiota composition at 6 months
of age, our results are in agreement with earlier studies
[5,29], except that we observed significant colonization
by bifidobacteria in most of the children (mean relative
abundances 22.9% at 6 months and 12.6% at 18 months
of age, respectively) while in the study of Palmer et al.
[29] bifidobacteria were not detected, possibly due to
differences in DNA extraction, PCR primers, demo-
graphic and geographic origin, dietary patterns of the
infants or other confounding factors. Primers used for
PCR are often not so optimal for bifidobacteria than for
other species and thus, high GC bacteria may perform
less well in such PCRs. Further, in our previous studies
we have shown that mechanical lysis of faecal bacteria is
essential and improves the detection of especially Gram-
positive bacteria including bifidobacteria [32,44]. In the
Palmer et al. study [29], mechanical lysis by bead-
beating was not applied, which may have hampered the
detection of bifidobacteria. Thus, we consider that the
most likely explanation for the different results concern-
ing bifidobacteria in our and Palmer et al. [29] study is
the different DNA extraction methods used.
When comparing healthy and eczematous children we
found statistically significant differences in microbiota
composition only at 18 months of age. The total micro-
biota of children with eczema was found to become sig-
nificantly more diverse than the microbiota of children
who remained healthy by 18 months of age. Interest-
ingly, the total microbiota and particularly Firmicutes di-
versity was higher in the eczema group children,
although the difference with the healthy subjects was
not statistically significant. Abrahamsson et al. described
the infants as having atopic eczema during the first two
years of life (diagnostics were done at 6, 12 and 24
months of age), but the age at the onset of symptoms
was not clarified [9]. However, it can be concluded from
the Abrahamsson et al. [9] and our study, both taking
advantage of the high resolution microbiota assessment
techniques, that after 1 year of age the total microbiota
diversity in children either developing or having eczema
is comparable or even higher than that of healthy chil-
dren. Secretory IgA has been suggested to play a role in
shaping the microbiota composition and diversity. Some
early studies showed an association between the low
levels of secretory IgA and the risk of developing atopy
[45,46] and could suggest that the low IgA levels permitestablishment of a wider variety of bacteria and explain
the higher bacterial diversity in children with eczema
observed in this study. However, more recent studies
have shown a higher concentration of secretory IgA in
children with allergic sensitization during the first 2
years of life [47,48].
Another possible explanation for the increased bacter-
ial diversity in children with eczema is the decreased
levels or altered repertoire of antimicrobial peptides
secreted into the gut lumen. These peptides, such as
alpha- and beta-defensins, have at least two key roles at
the mucosal interface: contributing to the host defense
against enteric bacterial attachment and homeostatic
control of the intestinal bacterial ecosystem [49,50]. Re-
cently, decreased alpha-defensin levels and increased
beta-defensin levels were associated with increased risk
of developing atopy [51]. To our knowledge, the levels of
faecal antimicrobial peptides in children already having
eczema have not been studied. However, a few studies
have highlighted the role of alpha-defensins in micro-
biota composition and intestinal health. For example,
genetic mutations resulting in decreased alpha-defensin
expression have been associated with the susceptibility
and severity of inflammatory bowel disease in humans
and decreased alpha-defensins may have an effect on the
differences observed in microbiota composition between
healthy and diseased subjects [52]. Interestingly, mice
deficient in production of active alpha -defensins were
shown to have a decrease in Bacteroidetes [50]. The rea-
son for decreased Bacteroidetes levels in children with
eczema in this study remains unaccountable, but alpha-
defensins provide one possible explanation for our ob-
servation. Also other host-dependent factors, such as the
amount of mucus secretion and differences in mucus
glycosylation (e.g. FUT2 secretor status) may have an in-
fluence on the microbiota diversity and composition, as
recently reviewed by Maynard et al. [53]. Clearly, the
role of intestinal IgA levels, antimicrobial peptides and
mucus secretion in shaping the gut microbiota in
healthy and eczematous children warrants for further
investigation.
Our results emphasize that the microbiota diversity in
children with eczema should be further studied by using
high-resolution techniques in order to define the
favourable course of bacterial succession in early child-
hood and toddler age and to evaluate possible means to
influence it.
It was observed that children with eczema harbour
more bacteria belonging to the Clostridium cluster IV
and Clostridium cluster XIVa. These bacteria are among
the most abundant microbial groups detected in the
healthy adult intestine [54]. Thus, prematurely occurring
changes towards an adult-type microbiota were observed
to take place in children with eczema. It has been
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physiology, among others, by modulating the expression
of genes involved in intestinal functions, such as postna-
tal intestinal maturation and the maintenance of muco-
sal barrier [55]. It may be speculated that an infant-type
microbiota supports adequate gut barrier function and
tolerance against food allergens in an immature gut.
Infant-type microbiota may fortify the normal mucosal
barrier function e.g. by affecting the maturation of the
gut epithelium and immune functions in an optimal way
and decrease the low-grade intestinal inflammation ob-
servable in subjects with eczema [53,56]. Maintenance of
adequate mucosal barrier function may also play a role
in the level of sensitisation to food-derived compounds
[57,58]. The complex host-microbe interactions in the
intestinal epithelium are only recently beginning to be
understood [53,59].
Furthermore, we observed decreased relative abun-
dances of bacteria belonging to Bacteroidetes in children
with eczema. Previous studies have reported an associ-
ation between decreased amounts Bacteroides spp. and
the development of atopy and increased risk for atopic
sensitization [9,60,61]. Bacteria belonging to the Bacter-
oidetes are among the first groups colonizing the gut
[15,29] and they are typical intestinal habitants in
healthy adults [62]. Bacteroides spp. are specialized in
the breakdown of complex plant polysaccharides [63]
and their abundance has been associated with increased
short-chain fatty acid concentrations in the infant gut
after introduction of first solid foods [64]. Furthermore,
B. fragilis polysaccharide has been shown in mice model
to direct the cellular and physical maturation of the
developing immune system via its ability to direct the
development of CD4+ T cells, thus inducing the differ-
entiation of Th1 lineage and correction of the Th1/Th2
imbalance [65]. Together with our findings, these results
suggest the significance of Bacteroides spp. in the devel-
opment and maintenance of healthy infant gut and
balanced mucosal immunity and necessitate the role of
these bacteria to be considered in future studies.
When comparing healthy children with children with
eczema we found statistically significant differences in
microbiota composition only at 18 months, but not at 6
months of age. Breast-feeding is known as a major factor
influencing the microbiota composition in infancy [4,5].
At 6 months of age, the majority of children included in
this study were still nursed and breast-feeding is likely to
have had a strong influence on their microbiota compos-
ition at that age. Thus, it seems that breast-feeding could
have evened up the microbiota differences between the
healthy and eczematous children and masked the
eczema-associated changes, which came apparent and
measurable at 18 months of age after the withdrawal of
breast-milk.While many studies addressed the impact of L. rham-
nosus GG on health parameters, the short and long-term
effect on the intestinal microbiota has only received lim-
ited attention. In the present intervention, the supple-
mentation of L. rhamnosus GG continued until the age
of 6 months. Interestingly, no significant effect on the
microbiota composition was observed at the age of 6
months, but instead the supplementation of L. rhamno-
sus GG in early life was observed to a induce long-term
effect and small but significant changes between the
intervention groups were observed one year later at the
age of 18 months. The observation that the C. difficile et
rel. group bacteria were lower in the LGG groups as
compared to placebo is of particular interest. Previously,
Clostridium difficile colonization at the age of 1 month
has been associated with a higher risk of a diagnosis of
atopic dermatitis at the age of 2 years [66]. The higher
Anaerostipes caccae et rel levels in the children that had
received the L. rhamnosus GG supplementation is also a
potentially beneficial effect, because A. caccae produces
butyrate, which is an energy source for epithelial cells of
colonic mucosa [67]. Bacteria belonging to the Eubacter-
ium ventriosum et rel group that were higher in the chil-
dren that received the probiotic supplementation, also
have shown to produce butyrate but have been less
investigated. In mice, however, it has been shown that E.
ventriosum was reduced in colitic mice as compared to
non-colitic animals [68]. To our knowledge this is the
first high -throughput microbiota analysis study report-
ing the long-term effects of a probiotic strain on the
microbiota composition in early life.Conclusions
In conclusion, using a comprehensive microbial analysis
approach we observed children with eczema to harbour
a more diverse total microbiota and detected specific
shifts in bacterial groups in different phylogenetic levels.
The results indicate that aberrancies in microbiota com-
position are associated with eczema. Our results also
suggest that in children at high-risk for atopic disease, a
diverse adult-type microbiota in too early childhood may
be a potential risk factor and further strengthen the im-
portance of early microbiota characterization and poten-
tial dietary modification.Additional files
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